Oral ciprofloxacin for osteomyelitis

Area of Science:

• Pharmacology
• Infectious Diseases
• Orthopedic Surgery

Background:

• Osteomyelitis presents a significant treatment challenge, often requiring prolonged antibiotic courses.
• Broad-spectrum antibiotics with favorable pharmacokinetic profiles are crucial for managing bone infections.
• Ciprofloxacin, a fluoroquinolone, offers potential advantages in treating complex infections like osteomyelitis.

Observation:

• Eighteen patients diagnosed with osteomyelitis were administered ciprofloxacin (750 mg orally twice daily).
• Treatment duration varied significantly, ranging from 5 to 52 weeks.
• Patient demographics included a mean age of 43 years, with 12 males.

Findings:

• A majority of patients (61.6%) achieved complete arrest of osteomyelitis infection.
• An additional 22.2% showed improvement in their condition with ciprofloxacin therapy.
• The antibiotic was generally well-tolerated, with a low incidence of adverse events reported.

Implications:

• Oral ciprofloxacin presents a viable and effective therapeutic option for osteomyelitis management.
• The drug's tolerability supports its use in long-term treatment regimens for bone infections.
• Further research can explore ciprofloxacin's role in diverse osteomyelitis patient populations and settings.